The effect of adjuvant M-VAC(methtrexate, vinblastine, doxorubicin and cisplatin) chemotherapy on advanced transitional cell carcinoma of the upper urinary tract.
- Author:
Byung Wook SEO
1
;
Dal Bong HA
;
Choal Hee PARK
;
Sung Choon LEE
Author Information
1. Department of Urology, Keimyung University, School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
advanced TCC;
M-VAC chemotherapy
- MeSH:
Carcinoma, Transitional Cell*;
Doxorubicin*;
Drug Therapy*;
Humans;
Urinary Tract*;
Vinblastine*
- From:Korean Journal of Urology
1992;33(4):632-636
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We treated 11 patients with advanced transitional cell carcinoma of upper urinary tract with adjuvant M-VAC chemotherapy and their median survival time was compared with 9 patients without M-VAC chemotherapy as e historical group. The total number of cycles per each patient ranged from 1 to 5 with a mean of 3.4. Of these patients, 8 patients could be evaluated for response and 4 patients were responded (2 complete and 2 incomplete. response rate 50%). The median duration of response was 26 months for complete responders and 4.5 months for incomplete responders. The median duration of survival for all chemotherapy group, complete responders, progression and historical control group were 22, 23+, 14 and 21 months. respectively. Median survival was 22 months in all 11 patients. 23+ months in clinical responders, 14 months in progression and 21 months in historical control group. Although overall survival was not prolonged significantly in chemotherapy than the historical control group, M-VAC was effective in small proportion of patients (CR: 2/8). The duration of survival of the patients with complete remission was prolonged significantly.
